Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stan Parker

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Frontiers in Sports and Active Living|August 21, 2024
A framework for player movement analysis in team sportsStan Parker, Grant Duthie, Sam Robertson
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2003
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumorsDavid Bushnell, Thomas O'Dorisio, Yusuf Menda, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastasesDavid Bushnell, Yusuf Menda, Mark Madsen, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Frontiers in Sports and Active Living|August 21, 2024
A framework for player movement analysis in team sportsStan Parker, Grant Duthie, Sam Robertson
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2003
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumorsDavid Bushnell, Thomas O'Dorisio, Yusuf Menda, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastasesDavid Bushnell, Yusuf Menda, Mark Madsen, et al.
Pageof 1